Search Results

You are looking at 1 - 3 of 3 items for

  • Author or Editor: Jorge Cerdá x
  • Refine by Content Type: All x
Clear All Modify Search
Jorge Cerdá

Acute kidney injury (AKI) does not discriminate in its impact. From the very young to the elderly, it can strike at any time, stems from a wide variety of causes, and demonstrates a complex variety of symptoms. The resulting kidney damage is often severe and life-threatening. Those who recover from AKI have a greater likelihood of important health consequences including recurrent AKI, progression to chronic kidney disease or end stage kidney disease, disability, and death.

Given the current state, in addition to developing newer paradigms and treatments, improvement in AKI outcomes will require a very large discussion involving all the

Jorge Cerdá and Bonnie L. Freshly

Acute kidney injury (AKI) affects people of all ages, races, genders, ethnicities, and socioeconomic status across the world. For those persons, the stakes are high: in the most severe forms of AKI, the associated morbidity and mortality are higher than those of other common critical conditions, such as acute respiratory distress syndrome and septic shock.

Most commonly, AKI is first encountered by a variety of non-nephrology healthcare providers, including primary care physicians, pediatricians, intensive care unit and emergency department providers, surgeons, nurses, advanced care providers, pharmacists, trainees, hospital administrators, and quality control experts.

Despite the ubiquity of AKI and its

Jorge Cerdá, Samir M. Parikh, Jay Koyner, Anitha Vijayan, Erin Barreto, and on behalf of the initiative

In hospitals and in the community, the incidence of acute kidney injury (AKI) is high and rising worldwide. At the societal level, AKI is increasingly recognized as a major public health burden (1). For the individual patient, severe AKI is a life-altering event with profound immediate and future consequences. Recently, the COVID-19 pandemic has highlighted the impact of AKI in hospitalized patients with SARS-CoV-2 infection.

AKI is not a single disease, but a syndrome caused by multiple mechanisms in patients with different comorbidities and several potential treatment targets. By developing the AKI!Now initiative, ASN is committed